Citius Oncology Inc (CTOR) FinancialsCTORCitius Oncology Inc

Evaluating the bottom line, Citius Oncology Inc maintains a gross margin of 67.07%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -583.54%, while the net margin is -597.40%. These profitability ratios, combined with a Return on Equity (ROE) of -126.58%, provide a clear picture of how effectively CTOR converts its operational activities into shareholder value.

In the context of the broader market, CTOR competes directly with industry leaders such as ANVS and MNOV. With a market capitalization of $84.59M, it holds a leading position in the sector. When comparing efficiency, CTOR's gross margin of 67.07% stands against ANVS's N/A and MNOV's 69.31%. Such benchmarking helps identify whether Citius Oncology Inc is trading at a premium or discount relative to its financial performance.

Citius Oncology has shown a gross margin of 79.99% in Q1 2026, indicating strong potential for profitability as it begins to generate revenue from its new drug, LYMPHIR. Despite this, the company has reported substantial net losses, including a $21.23 million loss in Q2 FY 2026, which raises concerns about its financial health.